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Background: Human aging is associated with DNA methylation changes at specific sites in the genome. These
epigenetic modifications may be used to track donor age for forensic analysis or to estimate biological age.
Results: We perform a comprehensive analysis of methylation profiles to narrow down 102 age-related CpG sites
in blood. We demonstrate that most of these age-associated methylation changes are reversed in induced
pluripotent stem cells (iPSCs). Methylation levels at three age-related CpGs - located in the genes ITGA2B, ASPA and
PDE4C - were subsequently analyzed by bisulfite pyrosequencing of 151 blood samples. This epigenetic aging
signature facilitates age predictions with a mean absolute deviation from chronological age of less than 5 years. This
precision is higher than age predictions based on telomere length. Variation of age predictions correlates
moderately with clinical and lifestyle parameters supporting the notion that age-associated methylation changes
are associated more with biological age than with chronological age. Furthermore, patients with acquired aplastic
anemia or dyskeratosis congenita - two diseases associated with progressive bone marrow failure and severe
telomere attrition - are predicted to be prematurely aged.
Conclusions: Our epigenetic aging signature provides a simple biomarker to estimate the state of aging in blood.
Age-associated DNA methylation changes are counteracted in iPSCs. On the other hand, over-estimation of
chronological age in bone marrow failure syndromes is indicative for exhaustion of the hematopoietic cell pool.
Thus, epigenetic changes upon aging seem to reflect biological aging of blood.Background
Aging reflects accumulation of cellular changes, due to
either stochastic defects or a regulated developmental
process [1]. This process is usually measured chrono-
logically, although it does not perfectly correlate with
time: 'biological age' is influenced by additional parame-
ters such as genetic background, disease and lifestyle.
Biomarkers for biological aging are relevant for geriatric
assessment and may support the adaptation of habits to
assist healthy aging [2]. Leukocyte telomere length has
been suggested as a marker for biological age [3]. In fact,
telomere attrition seems to be enhanced by various* Correspondence: wwagner@ukaachen.de
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reproduction in any medium, provided the orparameters, such as obesity and cigarette smoking [4].
Several other molecular methods can be used to esti-
mate human age, including analysis of age-dependent
deletions of mitochondrial DNA [5] or T-cell DNA rear-
rangements [6], and protein alterations such as racemi-
zation of aspartic acid [7] and advanced glycation end
products [8]. However, all of these biomarkers have rela-
tively low precision and practical limitations [9].
The epigenetic landscape provides new perspectives
for biomarkers. In particular, DNA methylation (DNAm)
is well known to change during aging [10]. Various
recent studies have demonstrated the presence of age-
related CpG sites (AR-CpGs), which are either hyper-
methylated or hypomethylated [11-14]. These DNAm
changes are significantly enriched in bivalent chromatin
domain promoters [15] and Polycomb group protein tar-
get genes [16-18], indicating that they might be gov-
erned by a developmental process. It is still not clearl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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or if they rather reflect an increased deviation of local
DNAm levels due to loss of control at specific loci [19].
Some CpG sites reveal almost linear DNAm changes
during aging and can therefore be used for age predic-
tion [19-21]. Bocklandt et al. [20] described a predictor
of age in saliva samples generated using DNAm profiles
from 34 twin pairs, indicating that age prediction based
on just a few CpG sites is feasible, although this has not
been validated in an independent set of samples. More
recently, Hannum et al. [19] built a quantitative model
of aging using DNAm values of 71 CpG sites that has
been validated on various independent datasets. How-
ever, these studies were based on Illumina BeadChip
technology, a method that requires complex bioinfor-
matic analysis. In this study, we address the question of
whether an assay based on bisulfite pyrosequencing of
just a few CpG sites might be a less costly, faster, and
user-friendly approach with similar accuracy to DNAm
profiling approaches. To this end, we pooled publicly
available DNAm profiles derived from blood samples to
identify AR-CpG sites that, when combined, best predict
donor age. Based on this analysis we developed an epi-
genetic aging signature that requires measurement of
DNAm levels at only three CpG sites by bisulfite se-
quencing to facilitate reliable age predictions. Notably,
these age predictions are influenced by clinical and life-
style parameters, indicating that they are more indicative
of biological age than chronological age.
Results
Age-related DNAm changes in blood samples
We combined 575 DNAm profiles derived from blood cells
from four different studies spanning an age range of 0 to
78 years (Table S1 in Additional file 1) [15,16,22,23]. All of
these DNAm profiles were generated with the Human-
Methylation27 BeadChip platform, which covers 27,578 in-
dividual CpG sites [24]. AR-CpGs with linear DNAm
changes during aging were selected by Pearson correlation
(either r > 0.85 or r < −0.85): 102 CpG sites passed these
stringent parameters, including 58 hypomethylated and 44
hypermethylated CpGs (Figure 1a; Additional file 2).
In particular, the hypomethylated AR-CpGs were associ-
ated with genes involved in 'hematopoietic regulation', indi-
cating that these age-related DNAm (AR-DNAm) changes
reveal some tissue specificity (Table S3 in Additional file 1).
Hypermethylated AR-CpGs were enriched within GC-rich
sequences (Figure S1a in Additional file 1) [13]. Predicted
transcription factor binding sites within 1 kb up- and
downstream of AR-CpG sites differed considerably for
hypo- and hypermethylated loci (Figure S1b in Additional
file 1). Furthermore, only hypermethylated CpGs were sig-
nificantly enriched in regions with bivalent histone modifi-
cations in embryonic stem cells (ESCs) and the H3K27me3(trimethylation of lysine 27 of histone 3) marker in mono-
cytes and mononuclear cells (Figure S2 in Additional file 1)
[25,26], which has also been described before [15]. Overall,
age-associated hypermethylation occurred particularly in
regions with low DNAm levels, whereas age-related hypo-
methylation occurred at highly methylated regions. This
trend towards a moderate methylation level has recently
been described by other authors and may support the no-
tion that many AR-DNAm changes are due to epigenetic
drift evoked by increasing entropy of CpG markers, which
tends towards 50% (Figure S3 in Additional file 1) [19,27].
Either way, the underlying mechanism resulting in AR-
DNAm changes at specific genomic regions seems to differ
for hypo- and hyper-methylated CpGs.
We trained a multivariate linear model to predict donor
age based on the 102 AR-CpG sites selected by Pearson
correlation. The results correlated well with chronological
age with a mean absolute deviation (MAD) from chrono-
logical age of only 3.34 years (root mean square error
(RMSE) = 4.26 years; R2 = 0.98; Figure 1b). These AR-CpG
sites were further validated in three other publicly avail-
able datasets derived from blood samples [28-30] using
the same multivariate linear model: the MAD from
chronological age in these datasets was only slightly higher
(GSE49904, 5.79 years; GSE41037, 5.52 years; GSE37008,
4.02 years; Figure S4a in Additional file 1). Furthermore,
we considered the recently published dataset by Hannum
and co-workers [19] of 656 DNAm profiles derived from
blood samples (from donors aged 19 to 101 years). This
dataset has been analyzed on the HumanMethylation450
BeadChip, which assays 485,577 CpG sites, including 99
of the 102 AR-CpG sites [31]. When we applied our multi-
variate linear model to this dataset, there was a clear cor-
relation between age prediction and chronological age
(R2 = 0.71). However, the linear offset indicated a system-
atic bias that might be due to the three missing CpG sites
or to the different assay design of the two microarray plat-
forms [31]. Therefore, we adjusted the multivariate regres-
sion model to facilitate age predictions based on these 99
AR-CpG sites, similar to the above-mentioned model
(MAD, 4.12 years; RMSE, 5.34 years; R2 = 0.87; Figure
S4b,c in Additional file 1).
Age-related DNAm changes are counteracted in
pluripotent stem cells
We have recently demonstrated that senescence-associated
DNAm changes - which accumulate during long-term cul-
ture of cells in vitro - can be reversed by reprogramming
into induced pluripotent stem cells (iPSCs) [32,33]. Here,
we analyzed if AR-DNAm changes are also reversed in this
dataset upon reprogramming: although our aging model
had been trained on freshly isolated blood samples, it en-
abled moderate estimations of age in culture-expanded
mesenchymal stromal cells as well. Notably, AR-DNAm
Figure 1 Age-associated DNAm is reversed by reprogramming into induced pluripotent stem cells. (a) A heatmap of 102 AR-CpG sites
from 575 DNAm profiles derived from blood cells from donors of different ages (HumanMethylation27 BeadChip platform). All of these loci
revealed relatively linear DNAm changes during aging (r < −0.85 or r > 0.85). (b) Based on these AR-CpGs, we generated a multivariate model to
predict donor age and these predictions were compared to the corresponding chronological age. A combination of all 102 AR-CpGs facilitated
reliable age predictions with a mean absolute deviation (MAD) of about 3.34 years. (c) Age-related-CpGs were subsequently analyzed in
mesenchymal stromal cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) (heatmap clustered by Euclidean
distance). Overall, AR-CpGs that are hypomethylated during aging are highly methylated in pluripotent stem cells and vice versa. (d) Subsequently,
we used a multivariate model to predict donor age in these cells (early passage, P2 or P3; late passage, P7 to P16). Notably, iPSCs generated from
these MSCs as well as ESCs were predicted to be of negative age, indicating that AR-DNAm changes are, overall, reversed by reprogramming into
pluripotent cells.
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ing culture expansion in vitro, indicating that AR-DNAm
changes are not identical to DNAm changes acquired dur-
ing in vitro culture (Figure 1c). Interestingly, CpG sites that
are hypermethylated during aging are hypomethylated in
pluripotent cells and vice versa. Using our multivariate
model, the ESCs and iPSCs were even predicted to be ofnegative age (Figure 1d), which may reflect the reversal be-
yond the new-born state to the embryonic cell state. How-
ever, when we applied our multivariate model to a dataset
with 19 undifferentiated human ESC lines and 5 iPSC lines
(GSE34869) [34], they were predicted to have a mean
donor age of −0.06 and 5.20 years, respectively (Figure S5
in Additional file 1). Thus, the deviation of ESCs and
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conditions or the comparison between different datasets.
Either way, the data clearly indicate that AR-DNAm
changes are, overall, reversed upon reprogramming. These
findings fit nicely with other recent observations that iPSCs
generated from senescent cells or centenarian donors reset
telomere length, gene expression profiles, and other
physiological features to those of young cells [35,36]. In
addition, our results indicate that iPSCs are rejuvenated
also on the epigenetic level.
Selection of the epigenetic aging signature
Analysis of DNAm in a small subset of AR-CpGs might
be sufficient for robust age predictions. Restriction to
the most relevant CpGs would facilitate site-specific ana-
lysis of DNAm instead of profiling approaches. There-
fore, we searched for subsets of AR-CpGs that, when
combined, yield the best age predictions. AR-CpGs with
the highest variation in DNAm levels were used for re-
cursive feature elimination to select subsets of five CpG
sites for testing in multivariate linear regression models.
Predictions for each of these subsets were made by itera-
tive divisions of the dataset into training and test sets
(split ratios; Figure 2a). For further analysis we consid-
ered only those subsets of five CpGs that performed bet-
ter than the average of models based on all 51 AR-CpG
sites (Figure S6 in Additional file 1). Five specific CpGs
occurred in more than 50% of the remaining subsets, in-
dicating that they complement each other for age predic-
tion (Figure 2b). These CpG sites are associated with
EDAR-associated death domain (EDARADD), which has
been associated with AR-DNAm changes before [20];
integrin, alpha 2b (ITGA2B); RAB36, a member of
the RAS oncogene family (RAB36); phosphodiesterase
4C, cAMP specific (PDE4C); and aspartoacylase (ASPA)
(Figure S7 in Additional file 1). Nevertheless, gene ex-
pression profiles indicated that expression of the five
corresponding genes is hardly affected by aging (Figure
S8 in Additional file 1) [37].
DNAm at these CpG sites was subsequently analyzed
by pyrosequencing after bisulfite conversion in an
independent training set derived from 82 blood samples.
The sequences in the vicinity of cg09809672 (EDAR-
ADD) and cg15379633 (RAB36) were not ideal for the
primer design and therefore we focused on the remaining
three AR-CpGs. As expected, we observed a clear age-
associated correlation for each of the three CpGs. In
fact, the upstream located CpG site cg17861230 (PDE4C),
which was covered by the same pyrosequencing assay,
revealed an even better age-association and was therefore
considered instead (Figure 2c,d). A multivariate linear
regression model based on these pyrosequencing results
facilitated age predictions with a MAD from chronologi-
cal age of 5.4 years (RMSE, 7.2 years; Figure 2e). Thecorresponding equation is provided in the Material and
methods section. To further simplify application of the
epigenetic aging signature, we have compiled an online
calculator that implements this equation [38].
Subsequently, we used this method on an independent
validation set derived from 69 blood samples; this valid-
ation set was analyzed two months after the training set.
DNAm levels at the three relevant CpGs were integrated
into the above mentioned linear regression model estab-
lished with the training set. Notably, the predictions for
the validation set correlated even better with chrono-
logical age (MAD, 4.5 years; RMSE, 5.6 years; Figure 2f ),
indicating that pyrosequencing of these three CpG sites
enables reliable age prediction.
AR-DNAm changes are not due to changes in the cellular
composition of blood
Our epigenetic age predictions might also be influenced
by differences in the cellular composition in blood that
result from aging [30]. Between the second and seventh
decade a moderate decline in lymphocytes [39] and eryth-
rocytes [40] has been described. When we analyzed
DNAm of the three relevant CpG sites (cg02228185 in
ASPA, cg25809905 in ITGA2B, and cg17861230 in
PDE4C) in a publicly available dataset of cell type-specific
DNAm profiles [41] the results indicated that the age
predictions made using our epigenetic aging signature
were not evoked by myeloid skewing (Figure S9a in
Additional file 1). Furthermore, we made age predictions
based on the three AR-CpGs using publicly available
DNAm profiles of fractionated monocytes (CD14), T cells
(CD4), granulocytes (CD16), and hematopoietic stem
and progenitor cells (CD34) (GSE20242; E-MTAB-487)
[15,42]. The results demonstrated that age predictions
were feasible in purified cell populations, even though the
MAD from chronological age was higher (Figure S9b in
Additional file 1). Alternatively, we used another dataset
to determine if the percentage of monocytes, lymphocytes,
neutrophils, basophils, or eosinophils correlates with pre-
dicted age and there were no clear associations (GSE37008;
Figure S10 in Additional file 1) [30]. These results indicate
that AR-DNAm changes are due to intrinsic DNAm
changes rather than to changes in cellular composition.
Clinical and lifestyle parameters
In an exploratory analysis to determine whether devi-
ation of predicted age and chronological age correlated
with other co-variables - such as clinical or lifestyle
parameters - we focused on the 105 samples from the
population-based prospective Heinz Nixdorf Recall
(HNR) study [43]. Generally, age was estimated to be
higher in men and in obese people (body mass
index >30). These trends are in line with previous stud-
ies demonstrating an association with telomere length
Figure 2 (See legend on next page.)
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Figure 2 Development of the epigenetic aging signature. (a) The most relevant AR-CpGs were selected by iterative division of 575 DNAm
profiles into training and testing sets (different split ratios). Age predictions were made for training sets using either 51 AR-CpGs or subsets of 5
CpGs. The results indicated that subsets with five CpGs (selected by recursive feature elimination) can enable age predictions with a mean
absolute deviation (MAD) from chronological age of less than 6 years. (b) The frequency of occurrence of individual AR-CpGs in the best
performing subsets of five CpGs. Five specific CpGs occurred in more than 50% of these filtered subsets and hence seemed to provide the best
complement for age predictions. (c) DNAm at relevant AR-CpG sites was subsequently analyzed by pyrosequencing after bisulfite conversion. The
sequences surrounding three of the five AR-CpGs were particularly suitable for this approach (CpG sites represented on the HumanMethylation27
BeadChip platform are indicated). (d) DNAm levels at these AR-CpGs were analyzed in a training set from 82 blood samples. The results were in
line with the microarray data and revealed a clear age-associated correlation for each of the three CpGs. For cg17861230 (PDE4C) this correlation
was even better at a neighboring CpG locus, which was therefore preferred for further analysis. (e) Based on the results with these three
AR-CpGs, we generated a multivariate model that enabled relatively precise age predictions (MAD of 5.4 years). (f) Notably, the precision was even
slightly higher when we validated this method in an independent set of 69 samples (MAD of 4.5 years).
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be explained by the relatively small sample size (Figure
S11 in Additional file 1). High alcohol consumption was
also associated with overestimation of age (0.091 ± 0.045
years deviation per gram alcohol consumed per day;
P = 0.049). Notably, age was increasingly underestimated
according to increasing number of children in women
(categories, 0, 1, 2, ≥3 children; -2.52 ± 0.84 years devi-
ation per category; P = 0.0043), which has been associ-
ated with a longer lifespan before (Figure 3) [47].
Age predictions correlate with telomere length
Telomere length is well known to decline during aging -
an average of 39 bp per year in granulocytes [48] - and this
approach can also be used to estimate donor age. We ana-
lyzed telomere length in 104 blood samples (from donors
aged 18 to 84 years) by flow-FISH. Despite a clear inverse
correlation between telomere length and chronological
age, the precision of age predictions based on telomere
length was relatively low (MAD, 18.2 years; RMSE,
23.1 years; Figure 4a; Figure S12a in Additional file 1).
Extremely shortened telomeres have been reported in
severe acquired aplastic anemia (AA) and patients withFigure 3 Parameters with age-independent impacts on AR-CpGs. Age
various clinical and lifestyle parameters (105 samples from the HNR study).
with (a) gender (P = 0.28), (b) body mass index (BMI; P = 0.67), (c) alcohol c
for females).dyskeratosis congenita (DKC), both of which are associ-
ated with progressive bone marrow failure syndromes.
Telomere attrition in these patients might result either
from increased hematopoietic cell turnover due to
autoimmune-mediated depletion of the hematopoietic
stem cell pool, or, particularly in DKC, due to direct
functional impairment of the telomerase complex by
inactivating mutations [49,50]. We analyzed blood from
15 AA and 5 DKC patients, which revealed significantly
shorter telomeres than healthy controls (Figure S12b in
Additional file 1). Notably, these samples were pre-
dicted to be significantly older than their chronological
age using our epigenetic aging signature, which may re-
flect replicative exhaustion of the hematopoietic stem
cell pool (Figure 4b,c) [18,49].
Discussion
We describe a method to predict donor age using blood
samples based on DNAm at three specific CpG sites.
The model is based on locus-specific pyrosequencing
analysis of bisulfite-converted DNA, an approach that is
relatively cost effective and does not require complicated
bioinformatics. Most importantly, the precision of ourpredictions with our epigenetic aging signature were associated with
Deviations from chronological age revealed a moderate association
onsumption (P = 0.049), and (d) number of children (P = 0.0043
Figure 4 Age-related DNAm correlates with telomere length. (a) Telomere length of granulocytes was analyzed by flow-FISH in samples from
104 healthy donors (grey), patients with aplastic anemia (AA; red) and dyskeratosis congenita (DKC; blue). (b, c) Age predictions with our
epigenetic aging signature demonstrated that several patients with AA or DKC - particularly those with telomere attrition - were predicted to
be significantly older than their chronological age (in comparison to age predictions for the validation set in Figure 2f).
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epigenetic approaches such as measurement of telomere
length, DNA rearrangements or protein alterations [9].
This assay can be used for forensic analysis of blood
samples - theoretically, it can even be scaled down for
relatively small traces of blood. Furthermore, our method
may enable estimation of biological age using blood. Such
predictions may be useful for geriatric assessment and
may help tailor lifestyle to improve the odds of staying
healthy. We provide evidence that deviation of predicted
age and chronological age might be associated with spe-
cific lifestyle parameters - for example, gender, body mass
index, alcohol consumption and the number of children -
but most of these effects were not significant, which might
be attributed to the relatively small sample size. On the
other hand, aging may vary between tissues and therefore
risk factors for age-related diseases - for example, in the
cardiovascular system - are not necessarily reflected in the
hematopoietic system.
AR-DNAm changes were suggested to be a tissue-
specific phenomenon [17,51]. Yet, we and other authors
have demonstrated that similar - but not identical - DNAm
changes are acquired in different tissues [15,16,19,21]. The
epigenetic aging signature described here has been specific-
ally designed for use with blood, which is advantageous
for practical diagnostics. Isolation of specific subsets,
such as B cells, T cells, or neutrophils, would be diffi-
cult to implement in daily routine, even if it would
further increase the precision of the method. Another
advantage is that DNA is relatively stable and can be
shipped at room temperature. Notably, the method
even enabled age predictions using samples that had
been cryopreserved for more than 10 years.
It is still not clear if and how AR-DNAm changes are
controlled. Our data support the notion that epigenetic
drift - in terms of Shannon entropy - occurs in certainregions that trend towards a DNAm level of 50% [19].
This may indicate that AR-DNAm changes are due to
loss of DNAm maintenance at specific regions; hyper-
methylation happens in regions associated with repres-
sive histone marks [15] and polycomb group protein
targets [16], whereas hypomethylation may be enriched
with other histone modifications, transcription factor
binding sites or chromatin organizations. Whether AR-
DNAm changes are the cause or consequence of aging
also remains to be elucidated. Even though many of
these AR-DNAm changes, including of the CpGs from
our epigenetic aging signature, are not reflected in gene
expression levels, it is well conceivable that the global
epigenetic shift that occurs during aging entails loss of
function in the elderly [52].
On the other hand, we provide evidence that AR-DNAm
changes can be reversed by reprogramming into iPSCs.
We have previously described that senescence-associated
DNAm changes, which are acquired during long-term
culture of mesenchymal stromal cells in vitro, are counter-
acted in iPSCs [33]. We have also demonstrated that
AR-DNAm changes and senescence-associated DNAm
changes differ considerably despite significant overlap [14].
This is in line with findings of this study as 102 AR-CpGs
could not separate mesenchymal stromal cells into those of
early and late passage. The observation that AR-DNAm
changes - as well as senescence-associated DNAm changes -
are reset to ground state supports the notion that pluri-
potency resets the aging clock: iPSCs generated from
senescent cells and cells from centenarian donors have re-
stored telomere length and their gene expression and
cellular physiology appear to be indistinguishable from
those of ESCs [35,36]. Notably, these cells can give rise
to new organisms that - at the beginning - do not reveal
any signs of aging. It is still not clear whether this 'epigen-
etic rejuvenation' can be disengaged from developmental
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passing through the pluripotent state [53]. The observa-
tion that AR-DNAm changes can be reversed indicates
that, molecularly, their acquisition over a lifetime might
be avoided and this is compatible with the evolutionary
theories of aging [54]. In this regard, aging would not re-
semble inevitable accumulation of genetic aberrations, but
rather a continuous deviation from the epigenetic ground
state - a loss of control that is not counteracted in somatic
cells and might be species- and tissue-specific.
Bone marrow failure in acquired AA and DKC has been
suggested to be associated with extensive proliferation of
hematopoietic stem cells [49,55]. DKC resembles an her-
editary syndrome evoked by mutations in the telomerase
complex or telomere-associated proteins whereas AA is
acquired due to autoimmune processes, toxic compounds,
or unknown factors. The degree of telomere shortening in
AA is correlated with disease duration, stage and severity
as well as with response to disease-modifying treatment
strategies [49]. In this regard, it is striking that those sam-
ples with stark telomere attrition in particular are also pre-
dicted to be prematurely aged by our epigenetic aging
signature. This observation further substantiates our
method, which may provide a diagnostic measure for the
replicative exhaustion of the hematopoietic stem cell pool.
Conclusions
Our comprehensive analysis of DNAm profiles discerned
AR-CpGs in blood. DNAm at three of these CpGs - de-
termined, for example, by bisulfite pyrosequencing - can
be used as a biomarker to enable age predictions with a
MAD from chronological age of about 5 years. The no-
tion that bone marrow failure syndromes, which are as-
sociated with telomere attrition, reveal premature aging
also at the epigenetic level may indicate that AR-CpGs
depict exhaustion of the hematopoietic stem cell pool.
Although our exploratory analysis suggests some associ-
ation with clinical or lifestyle parameters, it is still not
known if this analysis reflects biological age of the or-
ganism or rather of the hematopoietic system. It is also
not yet clear how AR-DNAm changes, which seem to
occur in a coordinated and reversible manner, are gov-
erned and if they are functionally relevant. AR-DNAm
changes may impact on chromatin structure or non-
coding RNAs even without having an immediate impact
on gene expression. Our epigenetic aging signature pro-
vides a simple approach that can be used to track the
aging process, which may be useful when further trying
to detail the underlying molecular mechanisms.
Materials and methods
Blood samples
We used blood samples from the HNR study, which is a
prospective population-based cohort study (105 samples)[43,56] from the Department of Obstetrics and Gynecology
of the University Hospital Aachen (GYN; 27 samples), and
from the Department of Oncology, Hematology and Stem
Cell Transplantation of the University Hospital Aachen
(HEM; 104 samples from healthy donors, 15 AA, 5 DKC).
All samples were taken after written consent and according
to the guidelines of the local ethics committees.
DNAm profiles and selection of AR-CpGs
We considered all DNAm profiles derived from blood
samples that were generated with the HumanMethyla-
tion27 BeadChip platform and available at the time
(Table S1 in Additional file 1). Beta values were com-
bined and 102 AR-CpG sites were selected by Pearson
correlation (r > 0.85 or r < −0.85). We trained a multi-
variate linear model for these AR-CpGs and applied
leave-one-out cross-validation to estimate the model's
performance. Age association of these CpGs was then
tested using datasets GSE49904 [28], GSE41037 [29],
GSE37008 [30], GSE34869 [34], and GSE20242 [15],
and E-MTAB-487 [42]. We also used dataset GSE40279
[19], although this was generated with the Human-
Methylation450 BeadChip (different assay design with
type II bead type and only 99 of 102 AR-CpGs) [31]
and we therefore trained an alternative model for use
with this platform.
Bioinformatics
Nucleotide sequences around each AR-CpG were re-
trieved from the human NCBI36/hg18 assembly. The
frequency of nucleotides in the flanking regions was
determined for 10 up- and downstream positions. FIMO
(Find Individual Motif Occurrences) from the MEME
Suite was utilized to scan for known transcription factor
binding motifs within 1 kb flanking each CpG sites. The
five most significantly enriched motifs in relation to all
CpG sites on the array were depicted (P-values were
estimated by Fisher’s exact test). The sequence logo plots
were generated by the R seqLogo packages. Histone
modifications at AR-CpG loci were analyzed using
chromatin immunoprecipitation data for ESCs [25]
(GSE8463 [26]; GSE29611, ENCODE project), CD14+
monocytes (GSE29611, ENCODE project), and MNCs
(GSE31755, ENCODE project). Enrichment of H3K4me3,
H3K27me3, the bivalent state or neither was estimated
in relation to all CpG sites (Fisher’s exact test). Gene
Ontology classification of genes associated with AR-CpGs
was performed with GoMiner software [57] in relation
to all CpGs on the BeadChip (Fisher’s exact test). For
the five most important AR-CpGs, we analyzed gene
expression data from the Leiden Longevity Study (150
samples; GSE16717) [37], which were generated with the
54 k CodeLink Human Whole Genome Bioarray. Methy-
lation profiles of our top three AR-CpGs in subsets of
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(GSE35069) [41].
Selection of CpGs for the epigenetic aging signature
To obtain a small set of AR-CpGs for age predictions
based on locus-specific DNAm levels, we narrowed 102
AR-CpGs down to those with above median variations in
beta values (above median level of interquartile ranges).
The dataset was then randomly divided into training
and validation sets by defined split ratios. Next we applied
recursive feature elimination implemented in the R caret
package [58] for a limited feature size of five CpGs using
a linear model on the training set. Relevant CpG sites
were then selected by their frequency in the best per-
forming models (Figure S6 in Additional file 1). The five
most relevant AR-CpGs were subsequently considered
for locus-specific DNAm analysis by pyrosequencing. The
sequences surrounding cg02228185 (ASPA), cg25809905
(ITGA2B), and cg17861230 (PDE4C) were best suited for
this approach.
Pyrosequencing and age predictions
Genomic DNA was isolated from GYN samples with
the QIAamp DNA Blood Midi Kit (QIAGEN, Hilden,
Germany; GYN), from HEM samples with the DNeasy
Mini Kit (QIAGEN), and from the HNR study samples
using the Chemagic Magnetic Separation Module I
(Chemagen, Baesweiler, Germany). Subsequently, 500 ng
DNA were bisulfite-converted using the EpiTect Bisulfite
Kit (QIAGEN). Converted DNA was amplified and 12 μl
(ASPA, ITGA2B) or 20 to 25 μl (PDE4C) of PCR product
was immobilized to 2 μl Streptavidin Sepharose™ HP
beads (GE Healthcare, Piscataway, NJ, USA) followed by
annealing to 1.0 μl sequencing primer (5 μM) for 2 mi-
nutes at 80°C. Primers for pyrosequencing analysis are
listed in Table S4 in Additional file 1. Analysis was per-
formed with PyroMark Q24 software. Initially, pyrose-
quencing was performed for 82 blood samples (27 GYN
and 55 HNR) at Varionostic GmbH (Ulm, Germany);
these samples were entirely independent from the DNAm
profiles that were used to identify the three genomic loca-
tions. Based on the pyrosequencing results of the initial 82
blood samples, we generated the multivariate model. Beta
values at the following three CpGs were used for age-
prediction: (α) = cg02228185; (β) = cg25809905, and (γ) = a
CpG site upstream of cg17861230 that revealed better cor-
relation with age (Figure 2c).
Predicted age in yearsð Þ ¼ 38:0‐26:4 α‐23:7 βþ 164:7 γ
This equation resembles also the underlying source
code for the freely available online calculator [38]. This
simple model was subsequently validated with an inde-
pendent set of 69 samples (19 HEM and 50 HNR).Biostatistics on clinical parameters
To estimate the impact of co-variables (for example, life-
style or clinical parameters), we calculated univariate linear
regression models using the deviation of predicted age and
chronological age as dependent variable and the respective
co-variable as independent variable (SAS, version 9.2, Cary,
New Jersey, USA). Similar models were computed separ-
ately for males and females to assess gender differences.
Some 52 male and 53 female donors from different age cat-
egories (intervals of 6 years per age category) were selected
randomly from the HNR study (4,814 participants) [56].
Box-and-whisker plots (10 to 90 percentiles) were plotted
with GraphPad Prism 5 (GraphPad Software, La Jolla, CA,
USA). Statistical significance was assessed from statistical
significance of parameter estimates of the linear regression
model depicting the change in deviation per one unit in-
crease in the corresponding co-variable.
Analysis of telomere length and age prediction
Telomere length of granulocytes and lymphocytes was
analyzed in 104 samples from healthy donors aged 18
to 84 years, 15 patients with AA, and 5 with DKC (all
HEM) by flow-FISH as described before [59,60]. In brief,
samples were analyzed in triplicates with and without
FITC-(C3TA2)3 PNA or Alexa488-(C3TA2) PNA (for
healthy controls or AA and DKC, respectively; Panagene,
Daejeon, South Korea). Cow thymocytes with known telo-
mere length were used as an internal control to calculate
telomere length in kilobases. The cow thymocytes as well
as granulocytes and lymphocytes from human samples
were identified based on forward scatter and LDS 751
binding to double-stranded DNA. For flow-FISH, telo-
mere length was determined in absolute values. Age-
related telomere length was estimated by linear regression
on the 104 blood samples from healthy donors.
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